Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Kathleen N. Moore(University of Oklahoma Medical Center), Toon Van Gorp, Tashanna Myers(Baystate Health), Jacqueline M. Tromp, Antoine Angelergues(Groupe Hospitalier Diaconesses Croix Saint-Simon), John W. Moroney(University of Chicago), Domenica Lorusso(Agostino Gemelli University Polyclinic), Yuemei Wang(ImmunoGen (United States)), Gottfried E. Konecny(University of California, Los Angeles), Rowan Miller(Queen Mary University of London), Susana Banerjee(Royal Marsden NHS Foundation Trust), Casey Cosgrove(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lucy Gilbert(McGill University Health Centre), Diana Bello-Roufai(Hôpital René Huguenin), Jung‐Yun Lee(Yonsei University), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Shani Breuer(Hadassah Medical Center), A. Roszak(Greater Poland Cancer Center), Nicoletta Colombo(University of Milano-Bicocca), Anna Berkenblit(ImmunoGen (United States))
Cited by 53
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882